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What is already known about this topic: 
- There is currently no review of the economic evidence within vitiligo. 
What does this study add? 
- This study highlights the lack of economic evidence within vitiligo, particularly surrounding the 
cost-effectiveness of currently prescribed treatments. 
- It is important that this research paucity is addressed. 
 
Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide 
prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-
pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. 
Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is 
frequently only prescribed for the face. 
It is important that decisions about how to spend limited healthcare funds are based on both the 
best clinical and economic evidence available. Often this is achieved by conducting an economic 
evaluation, a systematic process which aims to compare alternative courses of action in terms of 
their costs and benefits. Such analyses inform decisions by national bodies such as the UK National 
Institute for Health and Care Excellence. 
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Whilst there has recently been a gathering momentum for clinical research in vitiligo, possibly 
initiated by the James Lind Alliance priority setting partnership [2], along with a Cochrane systematic 
review which highlighted the existing lack of quality clinical research [3], it is unclear how much 
economic evidence is available within this clinical area. To investigate, we conducted a systematic 
review which aimed to identify all economic evidence related to vitiligo, to assess the quality of such 
economic research and lastly to identify any existing research gaps to help inform future research 
priorities. The full details of this systematic review are available online via the PROSPERO 
International Prospective Register of Systematic Reviews database [4], including the full search 
strategy and data extraction processes, whilst the PRISMA diagram detailing the results of the search 
process can be seen in Figure 1. 
This review identified only two published research papers with a primary economic objective within 
vitiligo [5, 6]. Radtke et al. [5] conducted a willingness-to-pay (WTP) survey of 3319 German vitiligo 
patients, receiving 1023 complete responses (a response rate of 30.8%). This involved questioning 
patients about how much they were willing to pay for a cure for their vitiligo. The WTP values 
reported can be considered to estimate the maximum potential for benefit should a cure be 
identified and indicates the personal burden of disease for a patient. Amongst the complete 
responses, 32.5% stated they would be willing to make a one-off investment of more than €5000 
(the highest band offered) for a cure of their vitiligo (2006 price year). The second paper found, 
conducted by Bickers et al. [6], considered the economic burden of multiple skin conditions, 
including vitiligo, across the United States. Using routinely collected data, this study estimated that 
the annual direct cost of treating vitiligo, which included visits to clinicians, hospital appointments 
and prescriptions, was $175,000,000 for the price year of 2004 (equivalent to £151,935,027.49, in 
2016) [7].  
Whilst these two papers do indicate both a great personal and health care provider cost associated 
with vitiligo, importantly they do not help to inform resource allocation decision making, given that 
neither paper considers both the costs and associated benefits of two or more treatment 
comparators. As no papers were identified that undertook full economic evaluations of vitiligo 
treatments, it is evident that treatment and prescribing guidelines are being developed in the 
absence of any economic evidence. This is in stark contrast to the number of full economic 
evaluations found within other dermatological conditions, for example, a total of 37 full economic 
evaluations were found in a recent systematic review within psoriasis [8], and highlights a great need 
for economic research in vitiligo. 
The systematic review does not enable us to answer our title question; it shows that no evidence 
exists to support or refute the value for money afforded by vitiligo treatments from any perspective 
(health systems, employers or individuals). It is hoped that this letter will act as a reminder to 
clinicians when conducting clinical effectiveness research to consider incorporating an economic 
component within this work. Particularly, there is a need for full economic evaluations considering 
currently prescribed vitiligo treatments. 
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PRISMA 2009 Flow Diagram:  
Search conducted from database inception to 31st May 2016 
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(n = 58) 
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(n = 56) 
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abstracts: 9 
Foreign Language: 7 
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